WuXi AppTec acquires OXGENE to further advance its cell and gene therapy service offerings for customers across the globe. Credit: Arek Socha / Pixabay.

WuXi AppTec has concluded the acquisition of UK-based contract research and development organisation OXGENE to boost its cell and gene therapy services for customers worldwide.

OXGENE will now be a fully owned subsidiary of WuXi Advanced Therapies (WuXi ATU), the cell and gene therapy Contract Testing, Development and Manufacturing Organisation (CTDMO) business unit of WuXi AppTec.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Transforming the development, testing, production and sale of cell and gene therapy products, the integrated platforms of the company expedite their time to market.

ROXGENE will retain its name and feature as WuXi ATU’s first facility in Europe, which will boost its capabilities.

OXGENE founder and CEO Dr Ryan Cawood said: “OXGENE is proud to have invented a range of next-generation platforms that address the complexities of viral vector manufacturing for gene and cell therapies.

“We are excited to join the team at WuXi ATU and to work together to scale up our technologies as a combined business, which will strengthen and broaden our service offerings for customers, improved by orders of the scale and cost of bringing cell and gene therapies to market.”

Founded in 2011, the company has provided discovery and biomanufacturing solutions to cell and gene therapy industries by using new technologies and contract research solutions.

Furthermore, it offers manufacturing systems that provide exceptional scalability.

Through its new TESSA technology for adeno-associated viral (AAV) manufacturing, as well as the XLenti stable solutions for lentiviral manufacturing, the company can streamline cell and gene therapy production and cut down costs.

WuXi ATU CEO Dr David Chang said: “By combining WuXi ATU’s world-class cell and gene therapy CTDMO platform with OXGENE’s innovative capabilities, we will be able to provide transformative solutions for our customers.

“This business combination represents a significant step in our ongoing effort to enable our customers and partners worldwide to deliver more effective and accessible advanced therapies to patients globally.”